Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage

Area of Science:

• Hematology
• Immunology
• Clinical Diagnostics

Background:

• Accurate quantification of circulating myeloma plasma cells is crucial for monitoring multiple myeloma.
• Existing methods like IgH-PCR have limitations in sensitivity and quantitative assessment.
• Flow cytometry offers potential for sensitive and quantitative detection of minimal residual disease.

Purpose of the Study:

• To develop and validate a flow cytometric assay for quantifying low levels of circulating myeloma plasma cells.
• To assess the relationship between circulating myeloma plasma cell levels and multiple myeloma disease stage.
• To compare the efficacy of flow cytometry with IgH-PCR for detecting residual disease.

Main Methods:

• Five-parameter flow cytometric analysis using a panel of antibodies to characterize plasma cells.
• Comparison of flow cytometry results with fluorescent consensus-primer IgH-PCR.
• Analysis of bone marrow and peripheral blood samples from multiple myeloma patients and healthy controls.

Main Results:

• Myeloma plasma cells were identified by high CD38 and Syndecan-1 expression, with distinct phenotypes differentiating them from normal plasma cells.
• Circulating myeloma plasma cells were detected in 75% of patients at presentation and 92% in relapse, but not in complete remission or normal controls.
• Flow cytometry results showed good correlation with IgH-PCR, accurately detecting residual disease and reflecting treatment response and disease progression.

Conclusions:

• Flow cytometry provides a sensitive and quantitative alternative to IgH-PCR for assessing minimal residual disease in multiple myeloma.
• The developed assay allows for effective monitoring of treatment response, refractory disease, and relapse.
• This technique can aid in personalized treatment strategies and improved patient management.